Cartesian Therapeutics, Inc. (RNAC)
| Market Cap | 351.42M |
| Revenue (ttm) | 34.17M |
| Net Income (ttm) | -38.31M |
| Shares Out | 25.95M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,377 |
| Open | 14.01 |
| Previous Close | 13.77 |
| Day's Range | 13.33 - 14.37 |
| 52-Week Range | 8.46 - 26.50 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 40.00 (+195.42%) |
| Earnings Date | Aug 7, 2025 |
About RNAC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an... [Read more]
Financial Performance
In 2024, Cartesian Therapeutics's revenue was $38.91 million, an increase of 49.64% compared to the previous year's $26.00 million. Losses were -$77.42 million, -69.90% less than in 2023.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RNAC stock is "Strong Buy." The 12-month stock price target is $40.0, which is an increase of 195.42% from the latest price.
News
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, t...
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmu...
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial
Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune dis...
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment ...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune dise...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseas...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points ...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:3...
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. Th...
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables pre...
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise Dr. Malik to deepen strategic leadership and provide regulatory and clinical development i...
Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
Cartesian Therapeutics, Inc. achieved positive results from the phase 2b study using Descartes-08 for the treatment of patients with myasthenia gravis; the End of phase 2 meeting with the FDA is expec...
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Cartesian Therapeutics said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial.
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune dis...
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 ...
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseas...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today annou...